FDA Approves Cladribine (Mavenclad) for Relapsing MS FDA Approves Cladribine (Mavenclad) for Relapsing MS

The US Food and Drug Administration today approved cladribine for treatment of patients with relapsing multiple sclerosis who have had insufficient response to other agents.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Alert Source Type: news

Related Links:

In this report we describe a rare case of concurrent AQP4-positive NMOSD and neurosyphilis. A 60-year-old man was admitted to our hospital with a complaint of progressive weakness in his legs for one month. T2-weighted magnetic resonance images of the spinal cord showed longitudinal extensive lesions at C7–T7. The rapid plasma reagin test and T. pallidum particle agglutination assay performed using patient serum and cerebrospinal fluid (CSF) were positive. Additionally, the AQP4-immunoglobulin (Ig) G was detected in the serum and CSF. The patient's symptom gradually improved after penicillin and methylprednisolo...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 22 June 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Tom A. Fuchs, Stefano Ziccardi, Michael G. Dwyer, Leigh E. Charvet, Alexander Bartnik, Rebecca Campbell, Jose Escobar, David Hojnacki, Chana Kolb, Devon Oship, Jeta Pol, Michael T. Shaw, Curtis Wojcik, Faizan Yasin, Bianca Weinstock-Guttman, Robert Zivadinov, Ralph H.B. BenedictAbstractBackgroundGrowing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusion: PwMS prioritize accessibility, affordability, insurance coverage, and comprehensiveness in MS healthcare services.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionCooccurrence of a seizure in a patient with MS may complicate the management process. In this review, we tried to provide answers to the frequently asked questions, considering the best available scientific evidence and expert opinion.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
ConclusionsThis study indicates that there was no significant correlation between IgG antibodies against Toxocara and variables such as gender and age. Based on the statistical analysis, there was no significant difference in Toxocara seropositivity between our control population with MS and RA patients.
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, aVoters for Cures advocate from South Carolina who reminds us what ’s at stake in the broader public policy debate around medical innovation, access and affordability.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development Drug Cost Multiple Sclerosis GoBoldly Source Type: news
Condition:   Multiple Sclerosis Intervention:   Dietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeks Sponsors:   University of Novi Sad, Faculty of Sport and Physical Education;   CarnoMed Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsing Multiple Sclerosis Intervention:   Drug: SAR442168 Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Multiple sclerosis (MS) and stroke are two common causes of death and disability worldwide. The relationship between these two diseases remains unclear. Effective early preventative measures and treatments are...
Source: BMC Neurology - Category: Neurology Authors: Tags: Research article Source Type: research
(1) Identify the proportion of participants with spinal cord dysfunction (SCD) reporting each of 10 job benefits and compare the proportions between participants with spinal cord injury (SCI) and multiple sclerosis (MS), and (2) examine if diagnostic criteria, demographics, education level, and functional limitations are associated with the number of job benefits received.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Source Type: research
More News: Brain | Drugs & Pharmacology | Food and Drug Administration (FDA) | Multiple Sclerosis | Neurology | Neurosurgery